



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

## Oversight Committee Meeting Agenda

**February 19, 2025**

8:30 a.m.

The Barbara Jordan Building  
1601 Congress Avenue, Austin, TX 78701  
Room 2.035A

The Oversight Committee may discuss or act on any item on this agenda, and as authorized by the Texas Open Meetings Act, Texas Government Code Section 551.001 et seq., may meet in closed session concerning any purpose permitted by the Act. If the Oversight Committee meets in closed session, it will do so in the Barbara Jordan Building, Room 2.027.

Also as authorized by Texas Government Code § 551.127, one or more Oversight Committee members may participate remotely in the meeting by videoconference. The Oversight Committee member presiding over the meeting will be physically present at the above-listed location, which will be open to the public.

Anyone wishing to offer public comments must notify the Chief Executive Officer in writing prior to the start of the meeting. The Committee may limit the time a member of the public may speak.

1. Call to Order
2. Roll Call/Excused Absences
3. Adoption of November 20, 2024, Meeting Minutes
4. Public Comment
5. Grantee Presentation
6. Chief Executive Officer Report
  - State Agency Employment Level
  - CEO Report Pursuant to Health & Safety Code § 102.260(c)
7. Chief Compliance Officer Report and Compliance Certification of Grant Award Process
8. Chief Scientific Officer Report
  - Grant Award Recommendations
9. Chief Prevention Officer Report
10. Chief Product Development Officer Report
  - FY 2026 Requests for Applications
11. Internal Auditor Report
12. Scientific Research and Prevention Program Committee Appointments
13. Advisory Committees
  - Advisory Committee Appointments
  - Advisory Committee on Childhood Cancer Presentation
14. Amendments to 25 T.A.C. Chapter 703
  - Amendments to Chapter 703 – Final Order

15. Chief Financial Officer Report
16. CPRIT Innovations VII Conference
17. Communications Program Update
18. Health & Safety Code Section 102.255(d) and Supplemental Guidance to the 2024 NIH Grant Policy Statement: Indirect Cost Rates
19. Subcommittee Business
20. Compliance Investigation Pursuant to Health & Safety Code § 102.2631
21. Consultation with General Counsel
22. Future Meeting Dates and Agenda Items
  - Proposed Board Retreat
23. Adjourn